<DOC>
	<DOCNO>NCT00657176</DOCNO>
	<brief_summary>This open-label , non-randomized , single-center , dose-escalation study patient advance solid tumor . Six dose level ( 100 , 200 , 400 , 600 , 800 , 1000 mg/day ) plan study . In study , OPB-31121 's potential toxic effect evaluate patient advance solid tumor evaluate recommend dose use subsequent study . The pharmacokinetics antitumor effect compound also investigate .</brief_summary>
	<brief_title>An Open-Label Phase-1 Study OPB-31121 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Histologically confirm solid tumor refractory standard therapy standard therapy 2 . Age : 19 year 3 . ECOG performance status : le 2 4 . Life expectancy longer 3 month 5 . Adequate vital organ function follow : Bone marrow function neutrophil : 1,500 per microliter platelet : 75,000 per microliter hemoglobin : 10.0g per deciliter Hepatic function AST ALT : less 2.5 x institutional upper limit normal serum total bilirubin : le 2.5 x institutional ULN Renal function Serum creatinine : le 1.5 x institutional ULN 6 . Capable swallow OPB31121 tablet 7 . Ability understand willingness sign write informed consent document participation trial analysis genotype CYP2C9 NAT2 8 . No chemotherapy , radiotherapy , surgery , immunotherapy within 4 week prior study entry recover prior toxicity Exclusion criterion : 1 . Symptomatic CNS metastasis 2 . Uncontrolled concurrent illness , include active infection , heart failure , angina pectoris , cardiac arrhythmia 3 . Psychiatric illness would limit compliance study requirement 4 . Pregnant breastfeed woman woman childbearing potential use effective contraceptive measure 5 . Administration another investigational agent within 6 month prior study entry 6 . Use CYP3A4 CYP2C9 inducer , inhibitor , substrate , CYP2B6 , CYP2C8 CYP2D6 substrates 7 . Hyperlipidemia : Total cholesterol : 300 milligram per deciliter Triglycerides : 2.5 x institutional ULN 8 . Abnormal thyroid function : Hypothyroidism hyperthyroidism grade 2 high ( grade accord NCICTCAE )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>